AstraZeneca Results Presentation Deck
Analysis: core operating profit and net debt
Increasing core operating profit; net debt was stable
$m
22
2,750
2,500
2,250
2,000
1,750
1,500
1,250
1,000
750
500
250
0
Q3 2017
Core operating profit reached $2,524m
Sources of profit continued to progress
Q4 2017
Q1 2018
Q2 2018
Return Return
to
to
sales revenue
growth growth
Q3 2018
Residual Collaboration revenue (CR) Core O01
Absolute values at actual exchange rates.
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Q2 2020
Q3 2020
Q4 2020
Q1 2021
$bn
12.1
Net debt end 2020
2.7
EBITDA
Net debt broadly stable
from improved EBITDA¹
1.2
Working capital, short-term provisions
0.8
Other operating cash, disposals
0.2
Capex
0.4
Contingent and intangible assets
and non-current asset investments
Net debt: $12,205m
EBITDA: $8,942m
2.5
Dividends
0.1
Other
AstraZeneca credit ratings:
1. Earnings before interest, tax, depreciation and amortisation; last four quarters ($8,942m vs. $6,974m one year ago)
Moody's: short-term rating P-2, long-term rating A3, outlook negative.
Standard & Poor's: short-term rating A-2, long-term rating BBB+, CreditWatch positive.
12.2
Net debt end March 2021
3View entire presentation